tDCS + Language Therapy for Primary Progressive Aphasia
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment for individuals with primary progressive aphasia (PPA), a condition that affects language skills. The treatment combines language therapy with transcranial direct current stimulation (tDCS), a non-invasive, safe, and potentially home-friendly method that uses mild electrical currents to stimulate the brain. The study aims to determine if this approach can improve communication for those with PPA. It seeks participants who have PPA and can understand the study details and consent to join. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important advancements in PPA treatment.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, if you are currently abusing alcohol or drugs, or participating in another trial, you may be excluded from this study.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that transcranial direct current stimulation (tDCS) is generally safe. In various studies, patients who received tDCS reported only minor side effects, such as mild tingling or itching at the application site. One study focused on individuals with primary progressive aphasia (PPA) and found that participants tolerated tDCS well, with no serious adverse effects reported. This suggests that tDCS could be a safe option for people with PPA considering clinical trials.12345
Why do researchers think this study treatment might be promising for aphasia?
Researchers are excited about the combination of transcranial direct current stimulation (tDCS) and language therapy for treating Primary Progressive Aphasia (PPA) because it offers a unique approach compared to current standard treatments like speech and language therapy alone. Unlike traditional methods, tDCS applies a gentle electrical current to the brain, potentially enhancing the effectiveness of language therapy by boosting brain plasticity and connectivity. This dual approach aims to improve language skills more effectively and efficiently, offering new hope for individuals with PPA who have limited options for significant improvement.
What evidence suggests that tDCS + Language Therapy might be an effective treatment for primary progressive aphasia?
This trial will compare two approaches: Active tDCS combined with language therapy and Sham tDCS combined with language therapy. Studies have shown that transcranial direct current stimulation (tDCS) can improve language skills in people with primary progressive aphasia (PPA). Research suggests that tDCS may enhance performance in naming tasks immediately and sustain improvement for up to two months. Early findings indicate that combining tDCS with language therapy might enhance the therapy's effectiveness. This treatment is gaining attention for its safety, ease of use, and potential affordability. While more large-scale studies are needed, early results are promising for those dealing with PPA.26789
Who Is on the Research Team?
Kyrana Tsapkini, PhD
Principal Investigator
Johns Hopkins University
Are You a Good Fit for This Trial?
This trial is for individuals aged 50-80 with non-fluent or logopenic primary progressive aphasia (PPA), who have at least a high school education and can consent to the study. Excluded are those with recent participation in other trials, left-handedness, pregnancy, severe cardiopulmonary disorders, pacemakers, terminal illness, major psychiatric issues that affect study compliance, previous skull breaches, certain MRI exclusions like claustrophobia or metal implants near the eye.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment Period 1
Participants receive Naming and Spelling (NASP) treatment with either active tDCS or sham condition for 3 weeks, with 5 language therapy sessions per week.
Wash-out
A 3-month stimulation-free period to evaluate clinically meaningful effects.
Treatment Period 2
Participants receive the alternate condition (active tDCS or sham) for another 3 weeks, with 5 language therapy sessions per week.
Follow-up
Participants are monitored for safety and effectiveness after treatment, including imaging and cognitive assessments.
What Are the Treatments Tested in This Trial?
Interventions
- Active tDCS + Language Therapy
- Sham tDCS + Language Therapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
Johns Hopkins University
Lead Sponsor
National Institute on Aging (NIA)
Collaborator
National Institutes of Health (NIH)
Collaborator